• Prior to 2007, the erythropoiesis-stimulating agents (ESAs) epoetin and darbepoetin were indicated for use in chemotherapy-induced anemia to a hemoglobin (Hb) level of approximately 12 grams per deciliter (gm per dL) and were to be withheld if Hb exceeded 13 gm per dL.
• At least 8 studies have shown that cancer patients with chemotherapy-induced anemia who received ESAs to a target Hb of more than 12 gm per dL have an increased risk of serious cardiovascular and thromboembolic events, mortality, and tumor progression.
• Starting in 2008, FDA label changes restricted initiation of ESAs to Hb below 10 gm per dL and use of the lowest dose of ESA necessary to avoid the need for a blood transfusion; if Hb exceeds a level needed to avoid transfusion, the ESA is to be withheld.
What is already known about this subject
www.amcp.org Vol. 14, No. 9 November/December 2008 JMCP Journal of Managed Care Pharmacy 859 M any chemotherapeutic agents used in the treatment of cancer increase the risk of anemia. 1 The development of anemia in cancer patients has been found to predict shorter survival times 2 and may be associated with fatigue that negatively impacts quality of life. 3, 4 Chemotherapy-induced anemia can be treated either by red blood cell transfusions or with erythropoiesis-stimulating agents (ESAs). Epoetin alfa (epoetin) and darbepoetin alfa (darbepoetin) are currently the only ESAs marketed in the United States.
Prior to 2007, both ESAs were indicated for use in chemotherapy-induced anemia to target a hemoglobin (Hb) level of approximately 12 grams per deciliter (gm per dL); treatment was to be withheld if Hb exceeded 13 gm per dL. 5, 6 Studies have demonstrated an increased risk of adverse events and poor disease outcomes when ESAs were used for treatment of anemia in patients with cancer who were not on chemotherapy or when used to target a Hb level exceeding 12 gm per dL. [7] [8] [9] [10] As a result, the U.S. Food and Drug Administration (FDA) mandated label changes for both epoetin and darbepoetin, adding boxed warnings in March 2007 that were updated in November 2007 and again in July 2008. The new labeling in 2008 stated that (a) ESAs are "not indicated for patients receiving myelosuppressive therapy when the anticipated outcome is cure," (b) "therapy should not be initiated at hemoglobin levels > 10 g/dL," and (c) "Withhold Dose if: hemoglobin exceeds a level needed to avoid transfusion." The ESA product label calls for discontinuation following completion of a chemotherapy course. 11 Because of findings of shortened survival and decreased time to progression of tumors in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers and increased risk of adverse cardiovascular and thromboembolic events, the ESA labels specify using the lowest dose necessary to avoid red blood cell transfusion and a target Hb range of 10 to 12 gm per dL. 12, 13 The boxed label warnings also emphasize that the use of ESAs to target HB levels could potentially still be associated with increased risk of poor disease outcomes. Current guidelines from the American Society of Clinical Oncology/American Society of Hematology 14 and the National Comprehensive Cancer Network 15 state that ESA treatment should be discontinued if Hb shows little or no response (i.e., less than 1-2 gm per dL increase in Hb or no reduction in need for transfusion) within 6-8 weeks (see Appendix A).
Because of the stricter limits placed on ESA use under current guidelines and labels, ESA treatment at Hb levels exceeding 12 gm per dL (ESAHb > 12) is unlikely to occur in the future. Yet, during the years when product labels did not explicitly contraindicate ESAHb > 12, many patients may have received treatment at higher Hb levels. Treatment patterns before and after patients received an ESAHb > 12 have not, to our knowledge, been examined.
The present retrospective study was designed to investigate patterns of ESA treatment and Hb levels among patients receiving the first chemotherapy regimen recorded in the database during the years [2002] [2003] [2004] [2005] [2006] . The goals of the study were to (a) quantify the prevalence and identify the predictors of receiving ESAHb > 12 and (b) describe patterns of treatment following the first administration of ESAHb > 12, in patients treated with chemotherapy and diagnosed with solid or hematologic cancer or myelodysplastic syndrome.
■■ Methods Data Source
The study data were obtained from the Varian Medical Oncology (Palo Alto, CA) database of electronic medical records (EMRs) from outpatient oncology practices. The database includes information on more than 150,000 cancer patients from 17 oncology provider organizations (13 community-based and 4 hospital-affiliated) comprising 71 clinic locations in the United States. At each patient visit to the clinic, the staff entered diagnoses, treatments, and other relevant information into the database. Diagnoses are entered as International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes, with no limit to the number that can be entered. Treatment data are entered as drug names and include orders or prescriptions for medications, with specifics such as dose and route, as well as duration of supply of oral medications and amount and timing of drugs administered in the clinic. Laboratory results were typically entered into the EMR The first chemotherapy regimen was defined as the earliest treatment plan for each patient in the EMR system (treatment regimen file); records of administration of chemotherapeutic drugs without a specified treatment plan were excluded. Non-myelosuppressive cancer regimens, such as monoclonal antibodies in the absence of cytotoxic chemotherapy, were excluded. Conventional myelosuppressive chemotherapies were those containing at least 1 cytotoxic chemotherapeutic agent; the most common regimens identified were carboplatin/paclitaxel, cyclophosphamide/doxorubicin, and fluorouracil/leucovorin/oxaliplatin (FOLFOX). The treatment plans include text descriptions of the drugs in the regimen; these text descriptions were standardized and classified according to whether or not they contained at least 1 conventional myelosuppressive agent. Qualifying agents included arsenic trioxide, azacitidine, bleomycin, capecitabine, carboplatin, carmustine, cisplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, dexrazoxane, docetaxel, doxorubicin, epirubicin, etoposide, fludarabine, fluorouracil, gemcitabine, ifosfamide, irinotecan, mechlorethamine, melphalan, methotrexate, mitomycin, mitoxantrone, oxaliplatin, paclitaxel, pemetrexed, streptozocin, topotecan, vinblastine, vincristine, and vinorelbine.
Patients with the following characteristics were excluded from the analyses: (a) first systemic cancer regimen was not conventional myelosuppressive chemotherapy (e.g., hormonal therapy or biologic therapy alone), (b) planned cycle length was not specified in the database or was longer than 60 days, or (c) there was a gap of more than 6 months between any 2 antineoplastic drug administrations during the first regimen. One of the 17 oncology provider organizations had a substantial amount of missing data on chemotherapy administrations; thus, patients treated by this provider were also excluded from the study. Follow-up data for each patient were obtained through December 31, 2006.
ESA Exposure
We identified the dates and doses of all ESA administrations that occurred during each patient's first chemotherapy regimen and found the closest Hb level measured on or within 7 days prior to the date of ESA administration. Because the analysis focused on treatment of chemotherapy-induced anemia and not anemia of cancer, only ESA administrations that occurred no more than 30 days after the most recent chemotherapy exposure were included. Patients who received at least 1 ESAHb > 12 were identified, and the date of their first ESAHb > 12 was noted. In a descriptive analysis of baseline demographic and clinical characteristics, the group of patients with ESAHb > 12 was compared both with the full population of eligible patients on chemotherapy and with the subset of the full population that received an ESA during chemotherapy with a known Hb level; patients receiving ESAs with no known Hb level were excluded from the ESA group.
We looked for any further use during the chemotherapy regimen of ESAs following the first ESAHb > 12 for each patient. The outcome measure included only ESA administrations that occurred within 30 days after chemotherapy and no more than 42 days apart. The 42-day restriction limited this analysis to ESA administrations that can be considered to fall within a single ESA episode of care. Up to 3 ESA administrations per patient following the first ESAHb > 12 were examined. The closest Hb level within 7 days before each administration was noted.
Analysis
Baseline characteristics were summarized using the information available in the EMR database on or before the start of the first chemotherapy regimen. We constructed a logistic regression model using all patients receiving chemotherapy with at least 1 recorded Hb level to identify factors associated with receiving ESAHb > 12. Variables entered into the model included age, gender, geographic region, year of regimen start, clinic type (communitybased or hospital-affiliated), type of health insurance (private, public, or other/unknown), cancer type (solid, hematologic, or multiple), binary indicator for platinum-containing chemotherapy, and lowest Hb level during the first regimen (lowest on or before the first ESA Hb > 12 for those with at least 1 ESAHb > 12). Patients lacking an Hb measurement at any time during the first regimen were excluded from the analysis.
A second logistic regression model, also examining receipt of ESAHb > 12, included only patients who received at least 1 ESA with a known Hb level. Because all patients without the outcome included in this model had by design an Hb level less than or equal to 12 gm per dL, this model did not include lowest Hb level as a predictor. A third model, identical to the first with respect to patients and variables entered, examined receipt of any ESA during the first chemotherapy regimen as an outcome. A final model sought factors associated with receiving further ESA treatment following the first ESAHb > 12. This model included only the patients with at least 1 ESAHb > 12 and contained the same variables as the first regression model, with the exception of using the Hb level associated with the first ESAHb > 12 instead of the lowest Hb level, and adding the specific ESA given at first ESAHb > 12 (epoetin or darbepoetin). All analyses were conducted using SAS version 8.2 (SAS Institute Inc., Cary, NC).
■■ Results
Of 27,450 patients who had provider-entered data on chemotherapy regimens in the treatment regimen file, we excluded those who started care in the oncology clinic outside of the study period, those lacking conventional chemotherapy or with unusual regimen data (i.e., recorded cycle length over 60 days or a gap in the regimen of at least 180 days), those younger than 18 years of age, those without a qualifying cancer diagnosis, and those who received care from the practice that did not adequately record drug administrations ( Figure 1 ). We identified 17,731 patients who met all inclusion criteria. Characteristics of all patients included in the cohort, all patients who received an ESA within 7 days of an Hb level measurement (n = 7,606, 42.9%), and the group of patients who received an ESA Hb > 12 (n = 1,844, 24.2% of ESA patients with known Hb value) are shown in Table 1 . In the full cohort, ages ranged from 19-97, with a mean (SD) age of 60 (13.2); 58.9% were female; and 66.7% lived in the southern United States. Most had solid tumor types, with breast (24.6%), lung (22.2%), and colorectal (15.8%) the most common. The cancer types were, for the most part, similar to national distributions reported by Surveillance Epidemiology and End Results (SEER), except that lung cancer was more common and prostate cancer largely underrepresented in this database from outpatient oncology clinics. 16 Of the full chemotherapy cohort of 17,731 patients, 8,086 (45.6%) received an ESA at any time during the regimen. At least 1 ESA associated with a known Hb level was administered to 7,606 patients (42.9%). A total of 1,844 patients (10.4% of the chemotherapy cohort, 24.2% of ESA users with a known Hb value) received at least 1 ESAHb > 12. Of the patients with at least 1 ESAHb > 12, the mean (SD) age was 62 (13.3); 63.7% were female; and 79.2% lived in the South. The distribution of tumor types was similar to that of the full cohort. Only 134 (7.3%) of the first ESAHb > 12 administrations were associated with Hb exceeding 13 gm per dL. Among the 7,606 patients treated with an ESA at a known Hb level, 1,226 of 3,006 epoetin users (40.8%) and 618 of 4,600 darbepoetin users (13.4%) received at least 1 ESA Hb > 12.
The logistic regression model of all chemotherapy patients ( > 12) was also associated with receiving at least 1 ESA Hb > 12; patients whose Hb fell below 11 gm per dL at any time during their regimen were most likely to receive ESAHb > 12, whereas those whose Hb remained above 13 gm per dL at all times were unlikely to receive an ESAHb > 12 (OR = 0.17, 95% CI = 0.12-0.24).
The model that included only the 7,606 patients who received an ESA with known Hb (Table 2 The logistic regression model of receiving further ESA treatment after the first ESAHb > 12 confirmed the between-drug difference in rates of continued ESA use (Table 3) . After adjusting for measured baseline factors, receiving epoetin as the first ESAHb > 12 remained a significant predictor of continuing ESA treatment, with an OR of 2.64 (95% CI = 2.04-3.41). first chemotherapy regimen. Many factors were found to predict receiving at least 1 ESAHb > 12. The strongest effects were seen for community-based compared with hospital-affiliated clinics, perhaps because physicians in community-based clinics may be reimbursed directly for each ESA administration, but hospital-based clinics receive pooled reimbursement. Additionally, patients having at least 1 Hb less than 11 gm per dL at some point during chemotherapy were more likely to be treated at higher Hb levels than were patients whose Hb values were consistently greater than or equal to 11 gm per dL. ESA treatment was more likely to continue in patients whose Hb dropped below 12 gm per dL after the first ESA Hb > 12, but still occurred in 25.9% of patients ([371+106]/1,844) when their Hb was between 12 and 13 gm per dL. These patterns are generally consistent with the prevailing guidelines for most of the study period, under which ESA treatment was initiated when Hb fell below 11 gm per dL, maintained to achieve an Hb of approximately 12 gm per dL, and withheld if Hb exceeded 13 gm per dL.
■■ Discussion
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Continuing ESA treatment after the first administration at high Hb levels occurred in 77% of patients on epoetin and 55% of those on darbepoetin. Patients on epoetin were more likely than those on darbepoetin not only to receive further ESA treatment, but also to have Hb again over 12 gm per dL at the time of the next ESA administration. Epoetin was administered to most patients on a weekly schedule and darbepoetin every 2 weeks. This difference in dosing schedule allows greater opportunity for further administrations of epoetin than darbepoetin during a given time window. To investigate the possibility that the restriction to a window of 30 days after the last chemotherapy administration could have biased the comparison between drugs with respect to further treatment, we conducted a sensitivity analysis using a 60-and a 90-day window after chemotherapy. The results using these 2 different time windows were essentially the same as those using a 30-day period. The 6-week follow-up duration for each patient allowed ample time for any further ESA treatment to appear, regardless of the original dosing schedule.
Limitations
To obtain an accurate picture of the treatment patterns occurring in oncology clinics, it is essential to use a database such as this EMR system rather than data from the tightly controlled environment of a clinical trial. Still, there are weaknesses inherent in these real-world data that one would not find in most controlled trials. First, Hb levels were not always measured or, in some cases, may have been measured but not entered into the EMR. Second, anemia-related symptoms may have prompted ESA treatment at these higher Hb levels and may explain some of the continued treatment seen, but information about symptoms was not consistently available in the database.
Third, red blood cell transfusions would also be expected to impact ESA treatment patterns, but again, these are not recorded reliably and, hence, were not examined in the present study. Because transfusions are indicated only at Hb levels well below 12 gm per dL, few if any members of the primary study group in the present analysis are likely to have received any transfusions following the first ESA administration at Hb over 12 gm per dL. Fourth, while it is possible to identify ESA nonresponders in an EMR system through ESA and data for Hb levels, we did not examine these data, since the focus of the present study was on the use of ESAs at high Hb levels and not on inadequate Hb elevations in response to treatment.
Finally, we included all cancer-related conditions that were associated with actual ESA use rather than restricting to only the indicated uses, since the purpose of the present study was to investigate the actual use of these drugs as supportive care for patients on chemotherapy. For example, we included myelodysplastic syndrome (ICD-9-CM 238.7), a condition that is not 
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approved in FDA labeling of ESAs but that, when treated with chemotherapy, has been associated with use of ESAs in oncology practice.
■■ Conclusions
We found that in the 5 years prior to product label changes made in 2007 and 2008, less than 11% of chemotherapy patients, representing 24% of all ESA users with a known Hb level, received an ESA at Hb levels above the 12 gm per dL upper end of the target range that was recommended during the study period. ESA treatment was subsequently withheld in 23% of epoetin users and 45% of darbepoetin users. Among ESA users with a known Hb level, factors predicting receipt of at least 1 ESA Hb > 12 were treatment in a community-based clinic, eastern region of the United States, private health insurance, and treatment year earlier than 2004. ESA use was more likely to continue following the first ESAHb > 12 among patients treated with epoetin than among those treated with darbepoetin. With new product labels, the factors associated with initiation and continuing ESA administrations in chemotherapy-induced anemia as well as use in off-label indications warrant further investigation once sufficient data are available.
Recommendations for chemotherapy-induced anemia (Summary from Rizzo et al. [2008] . 14 
I. General Recommendation
Recommendation
As in any medical situation, it is essential to consider other correctable causes of anemia before initiating therapy with stimulants of erythropoiesis. Therefore, it is advisable to conduct an appropriate history and physical, and to consider relevant diagnostic testing aimed at identifying causes of anemia aside from chemotherapy or underlying hematopoietic malignancy. At a minimum, one should take a thorough drug exposure history, carefully review the peripheral blood smear (and in some cases, the bone marrow), consider iron, folate, and B12 deficiency where indicated, and assess for occult blood loss and renal insufficiency. 
VIII. Iron Monitoring and Supplementation
Recommendation
Baseline and periodic monitoring of iron, total iron-binding capacity, transferrin saturation, or ferritin levels and instituting iron repletion when indicated, may be valuable in limiting the need for epoetin or darbepoetin, maximizing symptomatic improvement for patients, and determining the reason for failure to respond adequately to ESA therapy. There is inadequate evidence to specify the timing, periodicity, or testing regimen for such monitoring. There is no change to the recommendation from the 2002 guideline.
IX. Anemia in Patients Not Receiving Concurrent Chemotherapy
Recommendation
There is evidence that supports the use of epoetin or darbepoetin in patients with anemia associated with low-risk myelodysplasia. There are no published high-quality studies to support its exclusive use in anemic myeloma, non-Hodgkin's lymphoma, or chronic lymphocytic leukemia patients in the absence of concurrent chemotherapy. 
